What medication adjustments and monitoring are recommended for an 80-year-old female outpatient with diabetes, hypertension, hyperlipidemia, blood urea nitrogen 33 mg/dL, chloride 110 mmol/L, CO₂ 21 mmol/L, serum protein 6.1 g/dL, and estimated glomerular filtration rate 57 mL/min/1.73 m² (stage 3a chronic kidney disease)?

Medication Management for Stage 3a CKD with Diabetes, Hypertension, and Hyperlipidemia

For this 80-year-old stable outpatient with eGFR 57 mL/min/1.73 m² (Stage 3a CKD), diabetes, hypertension, and hyperlipidemia, initiate or continue metformin combined with an SGLT2 inhibitor as first-line diabetes therapy, use an ACE inhibitor or ARB for blood pressure control (especially if albuminuria is present), and monitor renal function and electrolytes every 3-6 months given the reduced eGFR. 1

Diabetes Management

First-Line Therapy

• Metformin: Continue or initiate at standard dosing since eGFR is 57 mL/min/1.73 m² (well above the 30 mL/min/1.73 m² threshold). Start with 500-850 mg once daily and titrate upward every 7 days to maximum tolerated dose 1
• SGLT2 Inhibitor: Add or continue an SGLT2i for both glycemic control and cardio-renal protection. This is a 1A recommendation for patients with diabetes and eGFR ≥20 mL/min/1.73 m² 1, 2
  • Choose agents with proven kidney/cardiovascular benefits (empagliflozin, dapagliflozin, or canagliflozin)
  • Expect a reversible 3-5 mL/min drop in eGFR initially—this is hemodynamic and not a reason to stop therapy 1
  • Consider reducing diuretic doses before starting to prevent volume depletion 1

Additional Therapy if Glycemic Targets Not Met

• GLP-1 Receptor Agonist: If A1c remains above target despite metformin and SGLT2i, add a long-acting GLP-1 RA (semaglutide or dulaglutide preferred for cardiovascular benefits) 1, 2

Hypertension Management

Blood Pressure Target and Monitoring

• Target BP: <140/90 mm Hg, with consideration for <130/80 mm Hg if tolerated without orthostatic symptoms 3, 4
  • In this 80-year-old, monitor for orthostatic hypotension and postprandial hypotension, which are common 5
  • Avoid diastolic BP <60 mm Hg, especially if coronary artery disease is present 5

Antihypertensive Selection

• ACE Inhibitor or ARB: First-line choice, particularly if albuminuria is present (check urine albumin-to-creatinine ratio if not already done) 1

  • Titrate to maximum tolerated dose
  • Monitor creatinine and potassium within 2-4 weeks of initiation or dose changes
  • Continue therapy unless creatinine rises >30% within 4 weeks 1
  • Never combine ACE inhibitor with ARB—this is potentially harmful 1

• Additional Agents: If BP not controlled, add calcium channel blocker or thiazide-like diuretic 3

Laboratory Monitoring Schedule

Renal Function

• eGFR and Creatinine: Every 3-6 months given eGFR <60 mL/min/1.73 m² 1
• Potassium: Check within 2-4 weeks after starting/adjusting ACE inhibitor or ARB, then every 3-6 months 1
  • If hyperkalemia develops (K+ >5.5 mmol/L), review concurrent medications (NSAIDs, potassium supplements), moderate dietary potassium, and correct volume depletion before stopping RAS inhibitor 1

Metabolic Parameters

• Bicarbonate (CO₂): Current level of 21 mmol/L is borderline low. Monitor for metabolic acidosis (treat if <18 mmol/L) 2
• Vitamin B12: Monitor annually while on metformin 1
• Albumin-to-Creatinine Ratio: Check if not recently done to guide intensity of RAS inhibition and consideration for nonsteroidal MRA 2

Additional Considerations for Nonsteroidal MRA

If albuminuria persists (ACR >30 mg/g) despite maximum tolerated RAS inhibitor and SGLT2i:

• Consider finerenone if potassium ≤4.8 mmol/L and eGFR >25 mL/min/1.73 m² 2
• Start 10 mg daily given eGFR 57 mL/min/1.73 m²
• Monitor potassium at 1 month, then every 4 months
• Hold if K+ >5.5 mmol/L 2

Critical Medication Adjustments

Metformin Dosing by eGFR

• eGFR 45-59 mL/min/1.73 m²: Consider dose reduction if on maximum dose; continue current dose if stable 1
• eGFR 30-44 mL/min/1.73 m²: Reduce to maximum 1000 mg daily (if eGFR declines to this range)
• eGFR <30 mL/min/1.73 m²: Stop metformin 1

Avoid in Elderly with CKD

• NSAIDs: Can worsen renal function and cause hyperkalemia
• Proton pump inhibitors: Most frequently inappropriate medication in elderly diabetics with hypertension (use only when clearly indicated) 6

Hyperlipidemia Management

• Continue statin therapy (dose adjustment generally not needed for Stage 3a CKD)
• Monitor for muscle symptoms given age and renal impairment

Lifestyle Modifications

• Physical activity: 150 minutes/week of moderate-intensity exercise, adjusted for fall risk 1
• Sodium restriction: <2 g/day to optimize BP control
• Weight management: Encourage weight loss if BMI elevated 1